help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online June 26, 2009
The Oncologist, Vol. 14, No. 10, 950-958, October 2009; doi:10.1634/theoncologist.2008-0070
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0070v1
theoncologist.2008-0070v2
14/10/950    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Robson, D.
Right arrow Articles by Verma, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robson, D.
Right arrow Articles by Verma, S.

Breast Cancer

Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?

Danny Robson, Sunil Verma

Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

Key Words. Adjuvant chemotherapy • Anthracyclines • Breast neoplasm • Cardiotoxicity • Leukemogenicity

Correspondence: Sunil Verma, B.Sc., M.D., M.S.Ed., F.R.C.P.C., T-Wing, 2nd Floor, Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada, M2N3E6. Telephone: 416-480-5248; Fax: 416-480-6002; e-mail: sunil.verma{at}sunnybrook.ca

Received March 24, 2008; accepted for publication May 23, 2009; first published online in THE ONCOLOGIST Express on June 26, 2009.

Disclosures: Danny Robson: None; Sunil Verma: Honoraria: AstraZeneca, Sanofi-Aventis, Pfizer; Research funding/contracted research: AstraZeneca, Sanofi-Aventis.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

Anthracycline regimens have been the mainstay of adjuvant care in breast cancer for >20 years. A growing body of clinical experience has uncovered an unacceptable rate of significant cardiac and leukomogenic toxicities. A systematic review of the literature was performed highlighting anthracycline- and nonanthracycline-based adjuvant regimens. The published data suggest that nonanthracycline alternatives are less toxic than anthracycline-containing regimens and equally, if not more, efficacious. Molecular predictors, such as human epidermal growth factor receptor 2 and topoisomerase II {alpha}, are further refining the optimal role of anthracyclines. With these new advances, the current role of anthracycline-based chemotherapy in early-stage breast cancer demands re-examination.




This article has been cited by other articles:


Home page
 The OncologistHome page
K. I. Pritchard
Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?
Oncologist, October 1, 2009; 14(10): 959 - 962.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.